Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada. more
Time Frame | MIST | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.53% | -2.12% | 0.77% |
1-Month Return | 3.91% | -2.54% | 2.65% |
3-Month Return | 27.4% | -6.28% | 12.3% |
6-Month Return | 25.68% | -1.36% | 13.48% |
1-Year Return | -41.88% | 9.29% | 33.47% |
3-Year Return | -67.02% | 10.05% | 32.22% |
5-Year Return | -88.89% | 43.69% | 92.85% |
10-Year Return | -87.9% | 103.1% | 194.31% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 15.00M | 15.00M | 5.00M | 1.00M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":33.33,"profit":true},{"date":"2023-12-31","value":6.67,"profit":true}] |
Cost of Revenue | 236.00K | 376.00K | - | 480.00K | 598.00K | [{"date":"2019-12-31","value":39.46,"profit":true},{"date":"2020-12-31","value":62.88,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":80.27,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (236.00K) | (376.00K) | 15.00M | 5.00M | 1.00M | [{"date":"2019-12-31","value":-1.57,"profit":false},{"date":"2020-12-31","value":-2.51,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":33.33,"profit":true},{"date":"2023-12-31","value":6.67,"profit":true}] |
Gross Margin | (Infinity%) | (2.51%) | 100.00% | 100.00% | 100.00% | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":-2.51,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 57.88M | 50.71M | 58.07M | 64.64M | 62.10M | [{"date":"2019-12-31","value":89.54,"profit":true},{"date":"2020-12-31","value":78.45,"profit":true},{"date":"2021-12-31","value":89.84,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.06,"profit":true}] |
Operating Income | (57.88M) | (50.71M) | (43.07M) | (59.64M) | (61.10M) | [{"date":"2019-12-31","value":-5788100000,"profit":false},{"date":"2020-12-31","value":-5071000000,"profit":false},{"date":"2021-12-31","value":-4307300000,"profit":false},{"date":"2022-12-31","value":-5964200000,"profit":false},{"date":"2023-12-31","value":-6109800000,"profit":false}] |
Total Non-Operating Income/Expense | 5.19M | 1.45M | 440.00K | 2.51M | 3.22M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":27.97,"profit":true},{"date":"2021-12-31","value":8.47,"profit":true},{"date":"2022-12-31","value":48.31,"profit":true},{"date":"2023-12-31","value":62,"profit":true}] |
Pre-Tax Income | (55.28M) | (49.98M) | (42.85M) | (58.39M) | (59.69M) | [{"date":"2019-12-31","value":-5528500000,"profit":false},{"date":"2020-12-31","value":-4998400000,"profit":false},{"date":"2021-12-31","value":-4285300000,"profit":false},{"date":"2022-12-31","value":-5838800000,"profit":false},{"date":"2023-12-31","value":-5968500000,"profit":false}] |
Income Taxes | (56.00K) | (17.00K) | (220.00K) | (1.25M) | (312.00K) | [{"date":"2019-12-31","value":-5600000,"profit":false},{"date":"2020-12-31","value":-1700000,"profit":false},{"date":"2021-12-31","value":-22000000,"profit":false},{"date":"2022-12-31","value":-125400000,"profit":false},{"date":"2023-12-31","value":-31200000,"profit":false}] |
Income After Taxes | (55.23M) | (49.97M) | (42.63M) | (57.13M) | (59.37M) | [{"date":"2019-12-31","value":-5522900000,"profit":false},{"date":"2020-12-31","value":-4996700000,"profit":false},{"date":"2021-12-31","value":-4263300000,"profit":false},{"date":"2022-12-31","value":-5713400000,"profit":false},{"date":"2023-12-31","value":-5937300000,"profit":false}] |
Income From Continuous Operations | (55.23M) | (49.97M) | (42.85M) | (58.39M) | (59.25M) | [{"date":"2019-12-31","value":-5522900000,"profit":false},{"date":"2020-12-31","value":-4996700000,"profit":false},{"date":"2021-12-31","value":-4285300000,"profit":false},{"date":"2022-12-31","value":-5838800000,"profit":false},{"date":"2023-12-31","value":-5925100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (55.23M) | (49.97M) | (42.63M) | (57.13M) | (59.69M) | [{"date":"2019-12-31","value":-5522900000,"profit":false},{"date":"2020-12-31","value":-4996700000,"profit":false},{"date":"2021-12-31","value":-4263300000,"profit":false},{"date":"2022-12-31","value":-5713400000,"profit":false},{"date":"2023-12-31","value":-5968500000,"profit":false}] |
EPS (Diluted) | (2.60) | (1.73) | (1.02) | (1.37) | (1.39) | [{"date":"2019-12-31","value":-260,"profit":false},{"date":"2020-12-31","value":-173,"profit":false},{"date":"2021-12-31","value":-102,"profit":false},{"date":"2022-12-31","value":-137,"profit":false},{"date":"2023-12-31","value":-139,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
MIST | |
---|---|
Cash Ratio | 14.53 |
Current Ratio | 15.40 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MIST | |
---|---|
ROA (LTM) | -33.09% |
ROE (LTM) | -133.75% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MIST | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.71 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.29 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MIST | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 91.95 |
P/B | 4.13 |
Price/FCF | NM |
EV/R | 81.44 |
EV/Ebitda | NM |
Milestone Pharmaceuticals Inc (MIST) share price today is $1.86
Yes, Indians can buy shares of Milestone Pharmaceuticals Inc (MIST) on Vested. To buy Milestone Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MIST stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Milestone Pharmaceuticals Inc (MIST) via the Vested app. You can start investing in Milestone Pharmaceuticals Inc (MIST) with a minimum investment of $1.
You can invest in shares of Milestone Pharmaceuticals Inc (MIST) via Vested in three simple steps:
The 52-week high price of Milestone Pharmaceuticals Inc (MIST) is $2.98. The 52-week low price of Milestone Pharmaceuticals Inc (MIST) is $1.12.
The price-to-earnings (P/E) ratio of Milestone Pharmaceuticals Inc (MIST) is
The price-to-book (P/B) ratio of Milestone Pharmaceuticals Inc (MIST) is 4.13
The dividend yield of Milestone Pharmaceuticals Inc (MIST) is 0.00%
The market capitalization of Milestone Pharmaceuticals Inc (MIST) is $98.66M
The stock symbol (or ticker) of Milestone Pharmaceuticals Inc is MIST